Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.

The role of histopathology in the diagnosis of essential thrombocythemia (ET) is controversial, and there has been little attempt to quantitate interobserver variability. Diagnostic bone marrow trephine biopsy specimens from 370 patients with ET by Polycythemia Vera Study Group (PVSG) criteria were assessed by 3 experienced hematopathologists for 16 different morphologic features and overall diagnosis according to the World Health Organization (WHO) classification. Our results show substantial interobserver variability, particularly for overall diagnosis and individual cellular characteristics such as megakaryocyte morphology. Reticulin grade was the dominant independent predictor of WHO diagnostic category for all 3 hematopathologists. Factor analysis identified 3 independent factors likely to reflect underlying biologic processes. One factor related to overall and lineage-specific cellularity and was significantly associated with JAK2 V617F status (P < .001), a second factor related to megakaryocyte clustering, and a third was associated with the fibrotic process. No differences could be discerned between patients labeled as having "prefibrotic myelofibrosis" or "true ET" in clinical and laboratory features at presentation, JAK2 status, survival, thrombosis, major hemorrhage, or myelofibrotic transformation. These results show that histologic criteria described in the WHO classification are difficult to apply reproducibly and question the validity of distinguishing true ET from prefibrotic myelofibrosis on the basis of subjective morphologic criteria. This study was registered at http://isrctn.org as #72251782 and at http://eudract.emea.europa.eu/ as #2004-000245-38.

[1]  J. Burston,et al.  The Reticulin Content of Bone Marrow in Haematological Disorders * , 1963, British journal of haematology.

[2]  C. Woods,et al.  Polycythaemia Vera and Myelosclerosis: A Bone Marrow Study , 1969, British journal of haematology.

[3]  P. Endes,et al.  Chronic idiopathic myelofibrosis. A reversible disease?. , 1977, Acta haematologica.

[4]  W. Bell,et al.  Essential thrombocythaemia. , 2016, Haemostasis.

[5]  J. Goldberg,et al.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. , 1986, Seminars in hematology.

[6]  G. Tobelem.  9 Essential thrombocythaemia , 1989 .

[7]  Y. Niitsu,et al.  The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis , 1990 .

[8]  M P Becker,et al.  Log-linear modelling of pairwise interobserver agreement on a categorical scale. , 1992, Statistics in medicine.

[9]  I T Joliffe,et al.  Principal component analysis and exploratory factor analysis , 1992, Statistical methods in medical research.

[10]  E. George,et al.  Journal of the American Statistical Association is currently published by American Statistical Association. , 2007 .

[11]  V. Diehl,et al.  Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. , 1996, Leukemia & lymphoma.

[12]  T. Pearson,et al.  The diagnostic criteria of polycythaemia rubra vera. , 1996, Leukemia & lymphoma.

[13]  J. Laszlo,et al.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.

[14]  W. Vainchenker,et al.  High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. , 1997, Blood.

[15]  P. Faccini,et al.  Prognostic significance of bone marrow biopsy in essential thrombocythemia. , 1999, Haematologica.

[16]  V. Diehl,et al.  Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) – a clinicopathological study , 1999, Leukemia.

[17]  H M Kvasnicka,et al.  Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. , 2000, Haematologica.

[18]  V. Diehl,et al.  Follow‐up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients , 2002, American journal of hematology.

[19]  J. Thiele,et al.  Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients , 2003, Annals of Hematology.

[20]  J. Thiele,et al.  Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features--a clinicopathological study on 272 patients. , 2003, Histology and histopathology.

[21]  T. Barbui,et al.  Efficacy and safety of low-dose aspirin in polycythemia vera. , 2004, The New England journal of medicine.

[22]  S. Rafii,et al.  Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis , 2004, Nature Medicine.

[23]  J. D. van der Walt,et al.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.

[24]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[25]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[26]  D. Steensma,et al.  The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. , 2005, British journal of haematology.

[27]  D. Steensma,et al.  The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .

[28]  A. Pancrazzi,et al.  A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. , 2005, Blood.

[29]  M. Loh,et al.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. , 2005, Blood.

[30]  M. Wadleigh,et al.  JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance , 2005, British journal of haematology.

[31]  Peter Congdon,et al.  Bayesian Models for Categorical Data , 2005 .

[32]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[33]  P. Guglielmelli,et al.  Clinical implications of the JAK2 V617F mutation in essential thrombocythemia , 2005, Leukemia.

[34]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[35]  W. Vainchenker,et al.  Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. , 2005, Cancer research.

[36]  Peter Congdon,et al.  Bayesian Models for Categorical Data: Peter Congdon/Bayesian Models for Categorical Data , 2006 .

[37]  R. Mesa,et al.  Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis , 2006, Cancer.

[38]  C. Harrison,et al.  The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia , 2006, British journal of haematology.

[39]  P. Campbell,et al.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.

[40]  R. Levine,et al.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. , 2005, Blood.

[41]  P. Campbell,et al.  The myeloproliferative disorders. , 2006, The New England journal of medicine.

[42]  W. Vainchenker,et al.  Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis , 2006, Leukemia.

[43]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[44]  W. Vainchenker,et al.  New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. , 2006, Seminars in thrombosis and hemostasis.

[45]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[46]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[47]  P. Campbell,et al.  Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. , 2006, Blood.

[48]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[49]  A. Tefferi,et al.  The diagnostic interface between histology and molecular tests in myeloproliferative disorders , 2007, Current opinion in hematology.

[50]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[51]  J. Herman,et al.  Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders , 2007, Leukemia.

[52]  Z. Berneman,et al.  WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. , 2007, Leukemia research.